Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation
Regulatory T cells (Treg)s attenuate excessive immune responses, making their expansion beneficial in immune-mediated diseases including allogeneic bone marrow transplantation (BMT)-associated graft-versus-host disease (GVHD). We have recently reported that Treg expansion does not require phospholipase Cγ activation when IL-2 is provided. As such, the combination of IL-2 and a calcineurin inhibitor (Cyclosporine A; CsA) expands Tregs while inhibiting Tconv proliferation and protects against a mouse model of multiple sclerosis. However, CsA inhibits Treg proliferation in the presence of a TCR stimulus, suggesting that CsA may negatively impact Treg proliferation when they receive strong allogeneic MHC-mediated TCR signals. In this study, we show that CsA inhibits Treg proliferation and inducible Treg generation in allogeneic but not in syngeneic BMT when IL-2 is provided. In contrast to CsA, the mTOR inhibitor (Rapamycin) almost completely suppressed IL-2-mediated Treg proliferation. However, CsA and Rapamycin inhibited Treg proliferation to a similar extent when TCR stimulation was provided. Furthermore, Rapamycin promoted Treg expansion and inducible Treg generation in allogeneic BMT recipients treated with IL-2. Consistent with these observations, CsA abrogated while Rapamycin promoted the protective effect of IL-2 on allogeneic BMT-induced GVHD. These results suggest that while CsA permits IL-2-induced Treg proliferation in the syngeneic setting (absence of strong TCR signals), CsA in combination with IL-2 may be detrimental for Treg proliferation in an allogeneic setting. Thus, in allogeneic settings, an mTOR inhibitor such as Rapamycin is a better choice for adjunct therapy with IL-2 in expansion of Tregs and protection against allogeneic BMT-induced GVHD.
References
[1]
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133: 775–787. doi: 10.1016/j.cell.2008.05.009
[2]
Josefowicz SZ, Rudensky A, Sakaguchi S, Yamaguchi T, Nomura T, et al. (2009) Control of regulatory T cell lineage commitment and maintenance Regulatory T cells and immune tolerance. Immunity 30: 616–625. doi: 10.1016/j.immuni.2009.04.009
[3]
Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336. doi: 10.1038/ni904
[4]
Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, et al. (2008) Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 14: 88–92. doi: 10.1038/nm1688
[5]
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144–1150. doi: 10.1038/nm915
[6]
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196: 389–399. doi: 10.1084/jem.20020399
[7]
Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723–735. doi: 10.1084/jem.20041982
[8]
Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A (2002) Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3: 33–41. doi: 10.1038/ni743
[9]
Bhandoola A, Tai X, Eckhaus M, Auchincloss H, Mason K, et al. (2002) Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. Immunity 17: 425–436. doi: 10.1016/s1074-7613(02)00417-x
[10]
Zou T, Caton AJ, Koretzky GA, Kambayashi T (2010) Dendritic cells induce regulatory T cell proliferation through antigen-dependent and -independent interactions. J Immunol 185: 2790–2799. doi: 10.4049/jimmunol.0903740
[11]
Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A (2009) Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood 113: 6277–6287. doi: 10.1182/blood-2008-06-161026
[12]
Satake A, Schmidt AM, Archambault A, Leichner TM, Wu GF, et al. (2013) Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells. J Autoimmun 44: 13–20. doi: 10.1016/j.jaut.2013.06.009
[13]
Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, et al. (1996) An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88: 3230–3239. doi: 10.1203/00006450-199604001-00931
[14]
Sawamukai N, Satake A, Schmidt AM, Lamborn IT, Ojha P, et al. (2012) Cell-autonomous role of TGFbeta and IL-2 receptors in CD4(+) and CD8(+) inducible regulatory T-cell generation during GVHD. Blood 119: 5575–5583. doi: 10.1182/blood-2011-07-367987
[15]
Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, et al. (2012) Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood 119: 5898–5908. doi: 10.1182/blood-2011-12-396119
[16]
Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, et al. (2012) CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol 189: 464–474. doi: 10.4049/jimmunol.1200886
[17]
Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, et al. (2011) Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118: 2342–2350. doi: 10.1182/blood-2010-10-313684
[18]
Zou T, Satake A, Ojha P, Kambayashi T (2011) Cellular therapies supplement: the role of granulocyte macrophage colony-stimulating factor and dendritic cells in regulatory T-cell homeostasis and expansion. Transfusion 51 Suppl 4160S–168S. doi: 10.1111/j.1537-2995.2011.03379.x
[19]
Wang Y, Camirand G, Lin Y, Froicu M, Deng S, et al. (2011) Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 186: 2809–2818. doi: 10.4049/jimmunol.0903805
[20]
Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, et al. (2008) Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+T cells. Blood 111: 453–462. doi: 10.1182/blood-2007-06-094482
[21]
Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142–1151. doi: 10.1038/ni1263
[22]
D'Cruz LM, Klein L (2005) Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6: 1152–1159. doi: 10.1038/ni1264
[23]
Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, et al. (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108: 390–399. doi: 10.1182/blood-2006-01-0329
[24]
Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375–387. doi: 10.1016/j.cell.2006.05.042
[25]
Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, et al. (2010) Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120: 1479–1493. doi: 10.1172/jci41072
[26]
Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, et al. (2007) Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109: 1756–1764. doi: 10.1182/blood-2006-08-042853
[27]
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, et al. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365: 2055–2066. doi: 10.1056/nejmoa1108188
